GlassScriptPhysician profile
Margaret D Workman
NPI 1043298144
$2,469.15
in general payments reported to CMS, 2019-2025
26 companies · $242 in 2025
The $242 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $331 · 2021: $278 · 2022: $417 · 2023: $473 · 2024: $359 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $497.12 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $309.84 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $258.25 | 2019-2025 | Vaxelis, Vaxneuvance, Rotateq |
| Ironshore Pharmaceuticals INC. | $255.15 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $204.62 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $140.81 | 2019-2022 | |
| Cranial Technologies, INC | $113.59 | 2019-2024 | Doc Band |
| Sanofi Pasteur INC. | $84.36 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $64.35 | 2023-2024 | Flumist Quadrivalent |
| Adlon Therapeutics L.P. | $63.42 | 2019-2021 | |
| Seqirus USA INC | $61.40 | 2021-2023 | Flucelvax Quadrivalent |
| Collegium Pharmaceutical, INC. | $54.36 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $44.03 | 2021-2022 | |
| Pfizer INC. | $39.70 | 2019-2023 | |
| Kaleo, INC. | $36.37 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $34.63 | 2021-2022 | |
| Ptc Therapeutics, INC. | $28.00 | 2023 | |
| Kyowa Kirin, INC. | $25.59 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.92 | 2023 | |
| Biogen, INC. | $24.52 | 2023 | Spinraza |
| Sobi, INC | $22.64 | 2019-2021 | |
| Lnhc, INC | $19.44 | 2025 | Zelsuvmi |
| Dermira, INC. | $17.51 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.26 | 2023 | Strensiq |
| Vertical Pharmaceuticals, LLC | $13.90 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.